Inventiva (IVA) completed the enrollment in a phase 3 clinical trial of lanifibranor in patients with metabolic dysfunction-associated steatohepatitis, a liver disease.
Enrollment targets were exceeded with 1,009 patients in the main cohort and 410 patients in the exploratory cohort, the company said Tuesday in a statement.
Completion of enrollment in the study before April 30 triggers the potential 116 million euros ($125.2 million) funding tranche of a structured financing of up to 348 million euros, Inventiva added.
Topline results of the study are expected in H2 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.